[Estrogens and progestins in hormone replacement therapy in menopause].

Although the use of hormone replacement therapy for menopause based on estrogens alone increases endometrial cancer risk, several studies indicate that combined therapy with estrogens and progestins is not related to an appreciable excess of endometrial cancer risk, if progestins are given for more than 10 or 14 days in each cycle. Combined therapy, however, may be associated to greater excess in breast cancer incidence as compared to estrogens alone.